ASCO 2023 | SCRUM-Japan GOZILA: evaluating the presence of NeoRAS metastatic colorectal cancer

Hiroki Osumi, MD, PhD, Japanese Foundation for Cancer Research, Tokyo, Japan, discusses findings from the SCRUM-Japan GOZILA study (UMIN000016343), which consisted of a nationwide screening platform for NeoRAS metastatic colorectal cancer (mCRC), which refers to RAS-mutant mCRC that becomes RAS wild-type during treatment. Liver and lymph node metastases and the presence of RAS mutations other than those in KRAS exon 2 were found to increase the likelihood of NeoRAS tumors. Dr Osumi additionally highlights EGFR inhibition as a promising treatment strategy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.